Anthrax countermeasures: current status and future needs.
The U.S. government does not yet have the range of medical countermeasures needed to protect its citizens from anthrax and other potential bioweapons. In the event of an anthrax attack, treatment interventions in addition to antibiotics would be needed so that very ill patients can be treated and clean-up crews can be better protected, especially if an engineered strain is used. This article describes specific anthrax countermeasures that are in development, barriers to development, and potential mechanisms the government could use to accelerate the movement of these countermeasures through the pipeline. A key challenge will be to encourage the transition of promising leads from basic research to the product development stage, when they may qualify for BioShield funds.
Center for Biosecurity of the University of Pittsburgh Medical Center, Baltimore, Maryland, USA.
Luciana L
LL
Borio
Gigi Kwik
GK
Gronvall
D000881:Anthrax / Q000188:drug therapy* / Q000517:prevention & control*; D022122:Anthrax Vaccines / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D023482:Bioterrorism; D004189:Disaster Planning / Q000458:organization & administration*; D004632:Emergency Medical Services; D006801:Humans; D014481:United States
D022122:Anthrax Vaccines; D000900:Anti-Bacterial Agents